SHANGHAI & CAMBRIDGE, Mass., November 13, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2026:
Zai Lab Ltd (ZLAB) posted $108.2 million in Q3 2026 revenue with a profitable China commercial business, $659.7 million in cash, and plans for a potential U.S. BLA submission for ZOSI in 2027.
SHANGHAI & CAMBRIDGE, Mass., November 05, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that updated data from a Phase 1b/2 trial of zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), will be shared tomorrow at the North American Neuroendocrine Tumor Society (NANETS) 2026 Multidisciplinary NET Medical Symposium in Las Vegas. The data indicate that zoci demonstrated clinically meaning
Zai Lab (NASDAQ:ZLAB) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings
ESMO data disclosure puts Zai Lab’s early lung cancer program in focus Zai Lab (ZLAB) has put fresh attention on its pipeline after confirming that global Phase 1b/1c data for zocilurtatug pelitecan in extensive-stage small cell lung cancer will appear at the ESMO Congress 2026. The ESMO update lands after a mixed period for Zai Lab, with the share price down 7.24% over the past 30 days, yet up 27.52% on a 90 day basis and 40.39% year to date, while the 1 year total shareholder return is...
Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the
Detailed price information for Zai Lab Ltd ADR (ZLAB-Q) from The Globe and Mail including charting and trades.
Zai Lab stock presents a challenging valuation picture for investors, with a share price that has risen in the shorter term but sits against a five year record of heavy value loss and only a mixed read from broader valuation checks. The share price has fallen 80.9% over the past five years, which points to a significant destruction of shareholder value over a full market cycle. Future revenue growth from its biopharmaceutical portfolio can support the current valuation, while ongoing...
Tipranks Press Release.
This is the newest page. Registered accounts read further back.